Daiichi Sankyo
Daiichi Sankyo is recorded as a service provider in 7 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 7 of 7 trials · Latest update first
A Phase 1b/2, Multicenter, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody-Drug Conjugate (ADC), in Combination with Atezolizumab with or without Carboplatin as First-line Induction or Maintenance, in Subjects with Extensive‑stage Small Cell Lung Cancer (ES‑SCLC) (IDeate-Lung03).
Sponsor Daiichi Sankyo Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Open-Label, Phase 2/3 Study of Datopotamab Deruxtecan (Dato-DXd) plus Carboplatin or Cisplatin versus Gemcitabine plus Carboplatin or Cisplatin in Participants with Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) who Progressed During or After Enfortumab Vedotin (EV) plus Pembrolizumab Combination Treatment. TROPION-Urothelial03 (TU03).
Sponsor Daiichi Sankyo Inc.
- Start (EU)
- Latest update
- Estimated end
PHASE 1/2, OPEN-LABEL, MULTICENTER, FIRST IN-HUMAN STUDY OF DS-3939a IN SUBJECTS WITH ADVANCED SOLID TUMORS
Sponsor Daiichi Sankyo Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2/3, Multicenter, Randomized Study of Raludotatug Deruxtecan (R-DXd), a CDH6-directed Antibody-drug Conjugate, in Subjects with Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Sponsor Daiichi Sankyo Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody-Drug Conjugate (ADC), Versus Treatment of Physician’s Choice (TPC) in Subjects with Relapsed Small Cell Lung Cancer (SCLC) (IDeate-Lung02)
Sponsor Daiichi Sankyo Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I DXd), a B7-H3 Antibody Drug Conjugate (ADC), in Subjects with Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) (IDeate Lung01)
Sponsor Daiichi Sankyo Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 1b/2 pan-tumor, open-label study to evaluate the efficacy and safety of ifinatamab deruxtecan (I DXd) in subjects with recurrent or metastatic solid tumors
Sponsor Daiichi Sankyo Inc.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Daiichi Sankyo?
The 2026-10-09 snapshot links Daiichi Sankyo to 7 distinct CTIS trials. Recorded services include Laboratory services, Biomarker testing, Archival Tumor Tissue Sample, Fresh Tumor Biopsy Sample, Archival Tumor Tissue Sample, Fresh Tumor Biopsy Sample, Blood Sample, among 6 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Daiichi Sankyo?
The most frequently recorded therapeutic areas are Solid Tumor Oncology, Respiratory, Urology. Recorded phases include Phase 2, Phase 1, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Daiichi Sankyo conducted?
The linked trials record locations in 17 countries, including Spain, France, Germany, Belgium, Italy. These are trial locations, not confirmed office locations or countries where Daiichi Sankyo delivered services.
What can this page tell me about Daiichi Sankyo's trial experience?
Browse 7 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Daiichi Sankyo. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Daiichi Sankyo Co. Ltd.